TABLE 2.
TT content administered at 2, 4, 6, and 12 months in Israel and 2, 4, and 6 months in Finlanda
| Regimen | TT content (μg) of vaccines administered
at each encounter at mo:
|
|
|---|---|---|
| 2, 4, and 6 | 12 | |
| Israel | ||
| PncT0 (placebo and PncD groups) | 54 | 54 |
| PncT03 | 78 | 54 |
| Finland | ||
| PncT0 (placebo and PncD groups) | 39 | NR |
| PncT01 | 48 | NR |
| PncT03 | 63 | NR |
| PncT10 | 111 | NR |
a
The TT contents in individual vaccines were as follows: DTP in Israel, 30 μg; DTP in Finland, 15 μg; PRP-T, 24 μg; PncT01, 9 μg; PncT03, 24 μg; and PncT10, 72 μg. NR, not relevant.